Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JAK2 inhibitor is focused on the treatment of myeloproliferative disorders and cancer
Subscribe to our email newsletter
Cytopia has filed an Investigational New Drug Application (IND) with the FDA for orally active JAK2 inhibitor, CYT387.
The company plans to start a phase I/II trial for CYT387 in patients with myelofibrosis, following the FDA review.
Clinical trial has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. The data suggests that the compound may exert a profound effect on the human disease.
Andrew Macdonald, CEO of Cytopia, said: The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team.
Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target, he added.